- WKN: A1EWWW
- ISIN: DE000A1EWWW0
- Land: Deutschland
Nachricht vom 15.10.2021 | 09:24
adidas AG: Release of a capital market information
/ Disclosure Pursuant to Article 2 (1) of Commission Delegated Regulation (EU) No 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR)
Herzogenaurach, October 15, 2021
Disclosure Pursuant to Article 2 (1) of Commission Delegated Regulation (EU) No 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR)
Purchase of Treasury Shares
The share buyback program announced by adidas AG (the "Company") via press release on October 14, 2021 will be conducted starting on October 18, 2021. Treasury shares of the Company with acquisition costs of up to € 450 million (excluding incidental purchasing costs), however in total no more than 12,839,970 shares, shall be repurchased via the stock exchange and/or a multilateral trading facility within the meaning of § 2 (6) German Stock Exchange Act (Börsengesetz) over a period of time until December 31, 2021 at the latest.
Whereas the Company may use the repurchased shares for all purposes admissible under the authorization granted by the Annual General Meeting on May 12, 2021, it intends to cancel at least most of the repurchased shares.
One or several independent banks may be assigned to carry out the buyback or parts thereof on behalf of and for the account of the Company. These banks make their decisions regarding the share buyback date independently of and uninfluenced by the Company. The Company's right to early termination of the mandate for one or all banks and/or to transfer the mandate to another bank or several other banks shall remain unaffected.
The share buyback program may be suspended, discontinued and resumed at any time in compliance with all applicable statutory provisions.
The mandated banks will be committed to observing all trading restrictions of Article 3 of the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016 ("EU Regulation"). All transactions under the share buyback program will be reported pursuant to the requirements of Article 2 (3) EU Regulation no later than on the seventh trading day after their execution. Furthermore, the Company will publish the transactions on its website www.adidas-group.com and ensure that the information will be publicly accessible there for a period of at least five years from the day of disclosure.
Herzogenaurach, October 15, 2021
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
04. Dezember 07:15 Bitcoin & Co: Brutaler Abverkauf – ist die Party jetzt vorbei?
04. Dezember 08:00 Top-Tipp Derivate: Luxus in der Warteschleife
04. Dezember 08:05 China-Aktien, Bitcoin & Co: Risiko-Assets werden verkauft
04. Dezember 08:45 Deutsche Telekom: 50 Prozent Potenzial - wann gelingt die Trendwende?
05. Dezember 07:00 Diese Token sind heißer als Bitcoin
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021